Tocilizumab: From Bench to Bedside - A Comprehensive Review.

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Interleukin-6 (IL-6) is a critical mediator in inflammation and cancer.
• Tocilizumab, an IL-6 receptor blocker, is vital for treating autoimmune conditions and managing cytokine release syndrome (CRS) in CAR-T cell therapy and bispecific antibody treatments.
• Global disparities exist in tocilizumab access and biosimilar adoption.

Purpose of the Study:

• To review clinical applications and safety of tocilizumab.
• To examine tocilizumab's role in oncologic and CRS-related conditions.
• To assess global access, pricing, and biosimilar availability of tocilizumab.

Main Methods:

• A PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses - Scoping Reviews) approach was employed.
• Evidence from published studies, clinical data, and economic reports was mapped.
• Included data covered approved and emerging indications, CRS management, and global market dynamics.

Main Results:

• Tocilizumab demonstrates consistent anti-inflammatory efficacy and a known safety profile in autoimmune diseases and COVID-19.
• It is the standard for moderate-to-severe CRS in CAR-T therapy and is increasingly used with bispecific antibodies.
• Biosimilars have reduced costs in high-income regions, but affordability and access remain issues in lower-income countries.

Conclusions:

• Tocilizumab is integral to autoimmune care, supportive oncology, and emerging cancer therapies.
• Future efforts should focus on enhancing biosimilar accessibility and refining CRS management strategies.
• Expanding high-quality oncologic trials for IL-6 blockade is a crucial next step.